You are about to leave Helsinn's Corporate US Website.

Please click 'Continue to external site' if you want to continue.

News

News

Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin, currently in development for treatment of anorexia-cachexia syndrom

Lugano, Switzerland, November 12, 2013 – Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly- owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.